Background and Purpose-There is some uncertainty about treating patients with atrial fibrillation (AF) with 1 nongenderrelated (NGR) stroke risk factor (CHA 2 DS 2 -VASc [ie, congestive heart failure, hypertension, age (≥75 years; 2 points), diabetes, stroke/transient ischemic attack (2 points), vascular disease, age (65-74 years), sex (female)] score of 1 in males and 2 in females) with oral anticoagulation (OAC). Methods-We investigated adverse outcomes and calculated the net clinical benefit of OAC use in a community-based cohort of unselected AF patients with 0 compared with 1 NGR stroke risk factor (CHA 2 DS 2 -VASc 0 versus 1 in males; and 1 versus 2 in females). Among 8962 patients with AF, 2208 (25%) had 0 or 1 NGR stroke risk factors, of which 45% were not prescribed OAC. Results-During a follow-up of 1028±1189 days (median, 495; interquartile range, 5-1882 days), the yearly rate of the combined end point of stroke/systemic embolism in nonanticoagulated AF patients with 1 NGR stroke risk factor was 2.09% (95% confidence interval, 1.37-3.18). This corresponded to an adjusted hazard ratio of 2.82 (95% confidence interval, 1.32-6.04) relative to the group with 0 NGR stroke risk factor. When the benefit of ischemic stroke reduction was balanced against the increased risk of intracranial hemorrhage among patients with 1 NGR stroke risk factor, the net clinical benefit was positive in favor of OAC use versus no antithrombotic therapy or antiplatelet therapy use. The net clinical benefit was negative for antiplatelet therapy use versus no antithrombotic therapy. Conclusions-Among AF patients with 1 NGR stroke risk factor (ie, CHA 2 DS 2 -VASc 1 in males or 2 in females), OAC use as indicated according to the guidelines was associated with a positive net clinical benefit for the prevention of stroke and thromboembolic events.
A trial fibrillation (AF) confers a substantial risk of fatal and disabling stroke. Randomized trials have conclusively demonstrated that compared with placebo, oral anticoagulation (OAC) reduces the risk of stroke/systemic embolism by 64% and all cause mortality by 26%. 1 Despite the excess risk of stroke and mortality with AF, this risk is not homogeneous and depends on the presence of various risk factors, which have been used to formulate various risk stratification schemes to guide thromboprophylaxis. Current guidelines recommend the use of the CHA 2 DS 2 -VASc (congestive heart failure, hypertension, age [≥75 years; 2 points], diabetes, stroke/transient ischemic attack (2 points), vascular disease, age [65-74 years], sex [female]) score, but the approach to treatment is different in different guidelines. [2] [3] [4] Some guidelines have focused on recommending OAC to high-risk patients with AF with at least 2 nongender-related (NGR) stroke risk factors (CHA 2 DS 2 -VASc ≥2 in males and ≥3 in females), but make no specific recommendation about antithrombotic choice for patients with only 1 NGR risk factor. 4 In contrast, the European Society of Cardiology (ESC) and National Institute for Health and Care Excellence (NICE) guidelines recommend a stepwise approach to risk stratification, where the initial step is to identify low-risk AF patients (ie, CHA 2 DS 2 -VASc score of 0 for males and 1 for females) who do not need any antithrombotic therapy, after which effective stroke prevention (ie, OAC) is offered to those with at least 1 NGR stroke risk factor (ie, CHA 2 DS 2 -VASc 1 in males or 2 in females). 3, 5 The aim of this study was to investigate adverse outcomes and calculate the net clinical benefit (NCB) of vitamin K antagonist (VKA) in a community-based cohort of unselected AF patients with 0 compared with 1 NGR stroke risk factor (CHA 2 DS 2 -VASc score 0 versus 1 in males; and 1 versus 2 in females). This would inform us whether a strategy focused on
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recommending OAC only to high-risk patients with at least 2 NGR stroke risk factors (CHA 2 DS 2 -VASc ≥2 in males and ≥3 in females) is appropriate.
Methods
Study Population
The detailed methods and design of the Loire Valley AF Project have been previously reported. [6] [7] [8] We included all patients seen in the cardiology department at the University Hospital of Tours between January 2000 and December 2010 with a diagnosis of AF and identified patients who were categorized as having 0 or 1 NGR stroke risk factors (ie, CHA 2 DS 2 -VASc score of 0 or 1 in males; and 1 or 2 in females).
AF (paroxysmal, persistent, or permanent) was defined on the ECG by the replacement of consistent P waves by rapid oscillations or fibrillatory waves that vary in amplitude, shape, and timing, associated with an irregular, frequently rapid ventricular response when atrioventricular conduction was intact. Treatment at discharge was at the discretion of physician in charge and was obtained by the screening of hospitalization reports. Patients were excluded from the study if their antithrombotic treatment at discharge was unknown. We also excluded from the analysis patients with a known mitral stenosis or any valvular prosthesis in whom OAC was theoretically indicated. Characteristics of the patients were obtained by the coding system filled in for each patient hospitalized through the computerized system of the institution, based on the International Classification of Diseases Tenth Revision. With these characteristics, the CHA 2 DS 2 -VASc score could be calculated retrospectively, as previously described 2 : that is, 2 points assigned for a history of stroke/transient ischemic attack/thromboembolism and age ≥75 years; 1 point assigned for age 65 to 74 years, history of hypertension, diabetes mellitus, recent cardiac failure, vascular disease (myocardial infarction, complex aortic plaque, and peripheral arterial disease), and female sex. VKA therapy was the only form of OAC used during the study period.
We defined 4 groups of patients. Group A=patients not treated with OAC with 0 NGR stroke risk factor, group B=patients not treated with OAC with 1 NGR stroke risk factor, group C=patients treated with OAC with 0 NGR stroke risk factor, and group D=patients treated with OAC with 1 NGR stroke risk factor, with subgroups A. During the follow-up of the patients, deaths from all causes and events of interest were recorded whenever they occurred in our institution, which includes a total of 4 hospitals covering all medical and surgical specialties. Our institution covers an area of 4000 km 2 and a population of 400.000 inhabitants and is the only public institution in the area. In addition, mortality data were obtained using a search tool from a dedicated website for the Région Center (http://nrco.lanouvellerepublique.fr/dossiers/necro/index.php).
OAC use reduces the risk of stroke/systemic embolism and allcause mortality. Thus, another adverse end point for this study was the composite of stroke/systemic embolism/death. Bleeding was defined with International Classification of Diseases Tenth version codes for bleed in any location. 9, 10 We also considered major bleedings, using the Bleeding Academic Research Consortium bleeding definitions. 11 We then compared the rate of events in nonanticoagulated patients with 0 (group A) or 1 NGR stroke risk (group B).
The NCB of antithrombotic strategy was calculated for patients with 1 NGR stroke risk factor in group B and group D, as originally proposed by Singer et al 12 using the formula:
NCB IS rate on no treatment IS rate on antithrombotic agen = − t t 1 5 ICH rate on no treatment ICH rate on antithromboti
where IS is the ischemic stroke and ICH, the intracerebral hemorrhage, which is the most serious form of bleeding associated with antithrombotic agent use. The NCB is used by clinicians and researchers as a validated method of balancing risk of IS against ICH. We also calculated the NCB of treatment using an alternate method, as proposed by Connolly et al, 13 which uses a weighted sum of rate differences ΔR=rate not treated−rate treated: NCB w1 RIS w2 RICH w3 Rmajor bleeding w4 RMI
where major bleeding refers to major extracranial bleeding, MI is the myocardial infarction and weights w1=1, w2=3.08, w3=0.67, and w4=0.95.
Statistical Analysis
Patient characteristics are reported as percentages and medians with interquartile range. Comparisons between groups were made using χ 2 tests for comparing categorical variables and the Student t test or nonparametric Kruskal-Wallis test were appropriate for continuous variables. Cumulative incidence rates of stroke, systemic thromboembolism, bleeding events, and all-cause mortality were calculated for all patients by groups and subgroups of interest. A Cox proportional hazards regression model was used to calculate the hazard ratio of some predictive factors and their 95% confidence interval for the incidence of events. We performed unadjusted and adjusted analyses (adjusted for baseline acetylsalicylic acid use for nonanticoagulated patients). A P value of <0.05 was considered statistically significant. Statistical analysis was carried out with the Statview 5.0 software (Abacus Concepts, Berkley, CA).
Ethics Approval
The study was approved by the institutional review board of the Pole Coeur Thorax Vaisseaux from the Trousseau University Hospital (Tours, France) on December 7, 2010 and registered as a clinical audit. Ethical review was therefore not required. Patient consent was not sought. Patient identifying data were used only to facilitate the cross referencing of data sources and records were otherwise anonymous. The study was conducted retrospectively, patients were not involved in its conduct, and there was no impact on their care.
Results
From 8962 unselected and consecutive patients with AF seen between 2000 and 2010, there were 2208 (25%) with <2 NGR stroke risk factors (ie, CHA 2 DS 2 -VASc score 0 or 1 in males; and 1 or 2 in females). Mean age was 55±14 and 685 (31%) were female. Baseline characteristics of the patients with AF and <2 NGR stroke risk factors are shown in Table 1 .
During a follow-up of 1028±1189 days (median, 495; interquartile range, 5-1882 days), outcomes (stroke, IS, stroke/ systemic embolism, myocardial infarction, death, bleeding, and the composite of death/stroke/systemic embolism) for nonanticoagulated AF patients with 0 compared with 1 NGR stroke risk factors are shown in Table 2 .
The yearly rate of stroke/systemic embolism in nonanticoagulated AF patients with 1 NGR stroke risk factor (CHA 2 DS 2 -VASc 1 in males and 2 in females) was 2.09% (95% confidence interval, 1.37-3.18). This corresponded to an adjusted hazard ratio of 2.82 (95% confidence interval, 1.32-6.04) relative to the group with 0 NGR stroke risk factor. For the death and the composite end point of death/stroke/ systemic embolism, the yearly rates were 3.78% and 5.59%, respectively, in nonanticoagulated patients with 1 NGR stroke risk factor versus 0.87% and 1.42% in nonanticoagulated patients with 0 NGR risk factors. In nonanticoagulated AF patients with 0 or 1 CHA 2 DS 2 -VASc factor (groups A+B), yearly rate of event was 0.65% for major Bleeding Academic Research Consortium bleeding and 0.43% for intracranial hemorrhage. There was a nonsignificant increase in hazard ratio for these events among the nonanticoagulated patients with 1 NGR risk factor (group B) relative to those with 0 NGR stroke risk factor (group A; Table 2 ).
Rates of IS, ICH, major extracranial bleeding, and myocardial infarction in AF patients with 1 NGR stroke risk treated with no VKA and no antiplatelet agent (subgroup B.1), antiplatelet agents and no VKA (subgroup B.2) and VKA and no antiplatelet agents (subgroup D.1) are shown in Table 3 . When the benefit of IS reduction was balanced against the increased risk of ICH among patients with 1 NGR stroke risk factor, the NCB was positive in favor of VKA use versus no 
CHA 2 DS 2 -VASc indicates congestive heart failure, hypertension, age (≥75 years; 2 points), diabetes, stroke/transient ischemic attack (2 points), vascular disease, age (65-74 years), sex (female); HAS-BLED, hypertension, age, stroke, bleeding tendency/predisposition, labile international normalized ratio, elderly age/frailty, drugs such as concomitant aspirin/NSAIDs or alcohol excess; NGR, nongender-related; and OAC, oral anticoagulation. antithrombotic treatment or VKA versus APT use, whether using the formula proposed by Singer et al 12 or that proposed by Connolly et al 13 (Table 4) . By contrast, NCB was negative for APT use versus no antithrombotic therapy.
Discussion
The NICE and European guidelines currently advise anticoagulation for patients with 1 NGR CHA 2 DS 2 -VASc score factor (ie, CHA 2 DS 2 -VASc 1 in males or 2 in females). In the US guidelines, OAC is recommended for patients with 2 NGR factors; whereas anticoagulation, APT, or no antithrombotic agent are all considered reasonable options for patients with CHA 2 DS 2 -VASc score 1. In this cohort study, our principal finding was that nonanticoagulated AF patients with 1 as opposed to 0 NGR stroke risk factor (CHA 2 DS 2 -VASc score of 1 versus 0 in males; and 2 versus 1 in females) had an increased risk of serious cardiovascular events during follow-up. Importantly, VKA use was associated with a positive NCB for the prevention of stroke and thromboembolic events in these patients.
The CHA 2 DS 2 -VASc score and older CHADS 2 score have 5 stroke risk factors in common, and previous guidelines already recommended OAC in patients with 1 stroke risk factor (eg, CHA 2 DS 2 score of 1). 14, 15 Thus, treatment guidelines unduly focused on identifying high-risk AF patients and only treating at least 2 NGR stroke risk factors (CHA 2 DS 2 -VASc score of ≥2 in males and ≥3 in females) with OAC should reconsider the positive NCB of OAC stroke prevention in AF patients with 1 NGR stroke risk factor. Indeed, strokes associated with AF are more likely to be fatal and disabling, and Adjusted HR indicates adjusted for baseline acetylsalicylic acid use; BARC, Bleeding Academic Research Consortium; CHA 2 DS 2 -VASc, congestive heart failure, hypertension, age (≥75 years; 2 points), diabetes, stroke/transient ischemic attack (2 points), vascular disease, age (65-74 years), sex (female); CI, confidence interval; HR, hazard ratio; and NGR, nongender-related.
by guest on November 17, 2017 http://stroke.ahajournals.org/ Downloaded from even 1 stroke risk factor confers a significant risk. The difference in annual IS rates between nonanticoagulated patients with 1 NGR stroke risk factor (1.08%) and those treated with OAC (0.91%) was statistically nonsignificant, probably because of a lack of power, but in these nonrandomized subgroups there was a lower rate of myocardial infarction in anticoagulated patients.
In contrast to VKA, APT was associated with a negative NCB when compared with no antithrombotic therapy, even when 1 NGR CHA 2 DS 2 -VASc stroke risk factor was present. The American College of Cardiology (ACC)/American Heart Association (AHA)/Heart Rhythm Society guidelines recommend no antithrombotic therapy, aspirin, or OAC for CHA 2 DS 2 -VASc score of 1; however, our findings do not support this strategy. Recent trials with non-VKA oral anticoagulant agents also provide data for benefit even with a single risk factor albeit with using the CHADS 2 score. Thus, physicians should appreciate that even a single NGR risk factor confers real risks of stroke/systemic thromboembolism/death, and OAC would reduce this overall risk, providing a positive NCB. Overall, this study supports the strategy for OAC proposed in the current ESC and NICE guidelines. 3, 5 We see the ability to report nonrandomized, real-world registry data from a large cohort of consecutive patients recruited as an advantage, not a weakness, in that the data are complementary (and supportive) to the data reported in randomized, clinical trials. In fact, a large randomized control trial addressing the issues presented here will probably not be performed. Observational studies such as ours may be of value because they shed light on the use of competing treatment options in current practice.
Limitations
The main limitation of this study is in its observational nature. Although adjusted for several variables, some patients might have more acute or severe illness and remains possible that residual confounding factors could exist in the analysis. 
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Concomitant drug therapies differed between groups and subgroups, and even after multivariate adjustment, our observational study design raises a question as to whether some groups or subgroups were merely managed better with a possible treatment bias, particularly those with VKA use. Although we carefully ascertained all strokes and ICH through examination and hospitalization records, laboratory and imaging results, patients with a milder form of stroke and ICH who were not hospitalized may have not been seen in hospital. In this realworld registry, some deaths could be because of undiagnosed stroke because cerebral imaging or postmortems were not mandated, unlike a clinical trial. Studies with a long-term follow-up as this one are often at risk of changes in treatment during the follow-up, which is impossible to make adjustments for in the multivariable analysis. Quality of anticoagulation with time in therapeutic range for patients treated with VKA use was not available. Another caveat is that we did not have access to data on strokes occurring outside of our area.
In conclusion, among AF patients with 1 NGR stroke risk factor (ie, CHA 2 DS 2 -VASc 1 in males or 2 in females), OAC use as indicated according to the ESC guidelines was associated with a positive NCB in favor of VKA use versus no antithrombotic therapy or aspirin. The NCB was negative for APT use versus no antithrombotic therapy. Guidelines focused on only treating at least 2 NGR stroke risk factors (CHA 2 DS 2 -VASc score of ≥2 in males and ≥3 in females) with OAC should reconsider the positive NCB of OAC stroke prevention in AF patients with only 1 NGR stroke risk factor (ie, CHA 2 DS 2 -VASc 1 in males or 2 in females).
